Vanda Pharmaceuticals received FDA approval for BYSANTI to treat Bipolar I and Schizophrenia
The stock surged 44% in after-hours trading following the announcement
BYSANTI has patent protection extending to 2044, protecting it from generic competition
The drug is being tested for major depressive disorder with results expected by end of 2026
📖 Full Retelling
Vanda Pharmaceuticals (NASDAQ: VNDA) announced on February 20, 2026, that it received FDA approval for its new drug BYSANTI, designed to treat Bipolar I manic episodes and Schizophrenia symptoms in adults, marking the company's second FDA win in less than two months and providing a long-term revenue moat with patent protection extending to 2044. The pharmaceutical company's stock surged 44% in after-hours trading as investors reacted positively to the announcement, with BYSANTI, also known as "milsaperidone," receiving faster approval than most new drugs due to its close relationship to an older medication called Fanapt. This approval comes just weeks after Vanda received FDA approval for NEREUS™ in December 2025, demonstrating the company's accelerating drug development pipeline and regulatory success in the competitive biopharmaceutical sector. BYSANTI offers a "trusted safety profile" backed by over 100,000 patient-years of real-world data due to its bioequivalence to iloperidone (marketed as Fanapt®), with the drug working by modulating dopamine and serotonin pathways while its unique "strong alpha-adrenergic binding" could make it a preferred treatment option for patients experiencing acute agitation and hostility. The company is currently testing BYSANTI as a treatment for major depressive disorder, with results expected by the end of 2026, which could significantly expand its market potential and future revenue streams, potentially forcing a reevaluation of Vanda's growth trajectory as its current market cap reflects a "Sell" or "Flat" analyst consensus.
🏷️ Themes
Pharmaceutical Approval, Stock Market Reaction, Drug Development, Intellectual Property
Schizophrenia is a mental disorder characterized variously by hallucinations (typically, hearing voices), delusions, disorganized thinking or behavior, and flat or inappropriate affect. Symptoms develop gradually and typically begin during young adulthood and rarely resolve. There is no objective di...
Bipolar disorder that is characterized by at least one manic or mixed episode
Bipolar I disorder (also referred to as BD-I or type one bipolar disorder) is a type of bipolar spectrum disorder characterized by the occurrence of at least one manic episode. Symptoms of bipolar I disorder typically begin at age 15-25 years of age, with depression being the most common initial sym...
# Food and Drug Administration (FDA)
The **Food and Drug Administration (FDA)** is a federal agency within the **United States Department of Health and Human Services (HHS)**. It serves as the primary regulatory body responsible for protecting and promoting public health in the United States.
### ...
No entity connections available yet for this article.
Deep Analysis
Why It Matters
The FDA approval of BYSANTI gives Vanda a strong, patent-protected product that can generate revenue for nearly two decades, boosting investor confidence. The 44% after-hours surge reflects the market’s recognition of a rare, high-margin opportunity in a small-cap biotech.
Context & Background
FDA approval of BYSANTI for Bipolar I and schizophrenia
Vanda's second FDA win in less than two months after NEREUS
Patent protection until 2044 gives a long-term revenue moat
What Happens Next
Vanda will focus on commercializing BYSANTI while awaiting results from its major depressive disorder trial expected by end of 2026. The company may also explore additional indications and expand its pipeline, potentially attracting new investors.
Frequently Asked Questions
What is BYSANTI?
BYSANTI, also known as milsaperidone, is a new chemical entity approved to treat Bipolar I manic episodes and schizophrenia symptoms in adults.
How long is the patent protection for BYSANTI?
The patent extends until 2044, giving Vanda almost two decades of market exclusivity.
What are the next steps for Vanda after this approval?
The company plans to launch the drug, monitor real-world data, and complete its major depressive disorder study expected by end of 2026.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump imposes new 10% global levy as SCOTUS strikes down sweeping tariffs Gold rises, silver jumps after disappointing economic data, SCOTUS tariff ruling Stocks end higher after SCOTUS tariff ruling, S&P 500 snaps two-week losing streak U.S. military operation in Iran "likely at this stage," Raymond James says (South Africa Philippines Nigeria) Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug By Investing.com Stock Markets Published 02/20/2026, 08:52 PM Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug 0 VNDA -5.57% Investing.com – Vanda Pharmaceuticals (NASDAQ: VNDA) just announced that it has received FDA-approval for its new drug known as BYSANTI. The drug is meant to treat Bipolar I manic episodes as well as Schizophrenia symptoms in adults. The approval marks Vanda’s second FDA win in less than two months, following the December approval of NEREUS™. A long-term revenue moat This is a major breakthrough for Vanda , given that the new drug has been categorised as a “New Chemical Entity”, a designation that usually comes with robust patient protection. The company’s patent of the new drug extends up to 2044. Therefore, it does not have to deal with generic competitors for almost two decades. Vanda stock surged 44% after-hours as investors piled into the stock after the announcement. BYSANTI™, also known as “milsaperidone” was approved much faster than most new drugs because it is closely related to an older drug called Fanapt. Leveraging a proven pedigree While BYSANTI is a new entity, it demonstrates bioequivalence to iloperidone (marketed as Fanapt®). This allows Vanda to enter the market with a "trusted safety profile" backed by over 100,000 patient-years of real-world data. The drug works by modulating dopamine and serotonin pathways, but its unique "strong alpha-adrenergic binding" could make it a preferred choice for patients suffering fr...
